NCT05429905View on ClinicalTrials.gov

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 18, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Lymphoblastic LeukemiaLymphoblastic Leukemia, Acute, ChildhoodLymphoblastic Leukemia in ChildrenLymphoblastic Leukemia, Acute AdultCAR
Interventions
BIOLOGICAL

Phase I

"* Dose level 0: CAR+CD3+ 0.4 x 10e6/kg (de-escalation dose)~* Dose level 1: CAR+CD3+ 1 x 10e6/kg (starting dose)~* Dose level 2: CAR+CD3+ 2.5 x 10e6/kg.~Dose-escalations for adults and paediatrics will be performed in 2 independent strata for determination of RP2D."

BIOLOGICAL

Phase II

RP2D will be determined in Phase I

Trial Locations (1)

Unknown

RECRUITING

KK Women's and Children's hospital, Singapore

All Listed Sponsors
collaborator

Singapore General Hospital

OTHER

collaborator

National University Hospital, Singapore

OTHER

lead

KK Women's and Children's Hospital

OTHER_GOV